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The interphase nucleus compartmentalizes its compo-
nents to give rise to a highly organized and tightly con-
trolled environment. Individual chromosomes occupy
discrete areas, termed “chromosome territories,” that
are separated from each other by a channel called the
“interchromosomal domain” (reviewed in Lamond and
Earnshaw 1998). Actively transcribed genes tend to be
at the periphery of chromosomal territories, whereas
newly made RNA transcripts localize into the inter-
chromosomal domain, where they can undergo further
processing and transport. Movement within the nucleus
(Ferreira et al. 1997) may permit chromosomes to enter
“factories” that contain all the necessary enzymatic ma-
chinery for replication (reviewed in Jackson 1995).
Of the many discrete domains identified throughout
the nucleus, the largest are nucleoli, sites of ribosomal
RNA synthesis and processing, and sites of preribosomal
particle assembly (reviewed in Scheer and Weisenberger
1994). Other subnuclear bodies that appear as punctate
structures under immunofluorescence (IF) microscopy
include various dynamic structures involved in the main-
tenance and replication of DNA and RNA synthesis,
processing, and transport (reviewed in Nickerson et al.
1995): replication foci, transcript foci, speckled do-
mains, coiled bodies, gems, and promyelocytic leukemia
protein (PML) nuclear bodies. Spliceosomal small nu-
clear (sn) ribonucleoprotein (RNP) components and a
subset of non-snRNP splicing factors can be found con-
centrated in discrete subnuclear domains called “coiled
bodies” (Matera and Frey 1998 [in this issue]). It is
becoming increasingly apparent that the nucleus has an
organization and contains a number of discrete mac-
romolecular domains that coordinate a variety of nu-
clear processes.
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Among these domains is a class of nuclear bodies that
were originally described as an autoantigenic target in
patients with primary biliary cirrhosis and were termed
“multiple nuclear dots” (reviewed in Sternsdorf et al.
1997). Several subsequent IF studies showed that the
human acute promyelocytic leukemia (APL) proto-on-
coprotein PML localizes to these distinctive nuclear dots.
They are known by a variety of names, including “PML
NBs” (PML nuclear bodies), “ND10” (nuclear domain
10), “Kr bodies,” “PODs” (PML oncogenic domains),
and “PML bodies” (reviewed in Doucas and Evans
1996). PML nuclear bodies vary in number between 10
and 30 per nucleus, and they typically have a diameter
of between 0.2 and 1mm, although their morphology and
size alters during the cell cycle. Analysis with immu-
noelectron microscopy has shown PML nuclear bodies
to be doughnut-like in shape, with a dense fibrillar ring
containing PML surrounding a central core that does
not contain PML (reviewed in Sternsdorf et al. 1997).
PML nuclear bodies appear to be nuclear matrix–
associated, because they are resistant to RNase and
DNase (Ascoli and Maul 1991) and they are detectable
in the residual insoluble fraction, although a soluble nu-
clear fraction of PML has also been observed (Muller et
al. 1998; M. N. Boddy and P. S. Freemont, unpublished
observations).
Components of PML Nuclear Bodies
At least 15 components have been identified as part
of the PML bodies (see fig. 1); some will be discussed
in this review.
PML and RFP
PML, one of the defining components of PML nuclear
bodies, acts as a cell-growth suppressor (Mu et al. 1994;
Ahn et al. 1995; Koken et al. 1995; Le et al. 1996). This
protein exists in many different isoforms, which vary in
size from 47 to 160 kD and are generated by alternative
splicing and variable C-terminal lengths (reviewed in
Grimwade and Solomon 1997), but all isoforms contain
several conserved cysteine-rich zinc-binding motifs,
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Figure 1 PML nuclear-body components and potential cellular
functions. PML nuclear bodies (large circle) comprise at least 15 com-
ponents (small circles; reviewed in Sternsdorf et al. 1997). They are
targets for viral infection and are disrupted in acute APL and in SCA1.
PML nuclear bodies may also play a role in transcription, cell growth
and regulation, antiviral defense, or storage of proteins.
known as the RING finger, B1, and B2 B-boxes (re-
viewed in Saurin et al. 1996). These domains are fol-
lowed by a predicted a-helical coiled-coil region, all of
which together form a tripartite motif known as the
RBCC motif, which is thought to mediate assembly of
PML nuclear bodies. Recently, it has been shown that
the coiled-coil domain can form a hetero-oligomeric in-
teraction with another RBCC protein called ret finger
protein (RFP), another component of PML nuclear bod-
ies (Cao et al. 1998). RFP becomes oncogenic when
fused to the RET proto-oncogene (Takahashi et al.
1988). RFP associates with only a subset of PML nuclear
bodies, possibly reflecting the dynamic nature of these
structures.
ISG20 and INT6
ISG20 colocalizes with PML nuclear bodies and has
homology with the Xenopus protein XPMC2, a negative
regulator of cell division (Gongora et al. 1997). INT-6,
a putative dominant negative oncoprotein, also colo-
calizes with PML nuclear bodies (Desbois et al. 1996),
which are delocalized as a result of viral infection (see
below).
PIC1/SUMO-1 and HAUSP
PIC1/SUMO-1 is a ubiquitin-like protein that cova-
lently modifies PML (Boddy et al. 1996; Muller et al.
1998). This modification is reversible and phosphory-
lation-dependent, with the unmodified PML found in
the soluble nucleoplasmic fraction, whereas the modified
form apparently partitions into the nuclear matrix (Mul-
ler et al. 1998). PIC1/SUMO-1 has 73% homology at
the protein level with the SMT3 protein from Sacchar-
omyces cerevisiae (Boddy et al. 1996). SMT3 is an es-
sential yeast gene and was described as a high copy sup-
pressor of mutations in MIF2, whose product is required
for mitotic spindle integrity at anaphase. The mecha-
nisms by which PIC1/SUMO-1 is conjugated to and re-
moved from PML are beginning to be understood. One
member of the ubiquitin-specific protease family,
HAUSP, is found in PML nuclear bodies (Everett et al.
1997), but it fails to cleave PIC1/SUMO-1 modified pro-
teins (Everett et al. 1998).
CBP and pRB
Cyclic AMP response element–binding factor (CREB)-
binding protein (CBP) is a coactivator for a variety of
transcription factors, including nuclear hormone recep-
tors, and it possesses histone acetyl transferase activity
(reviewed in Shikama et al. 1997). In interphase nuclei,
CBP has a microparticulate distribution with a few larger
dots, which colocalize with PML nuclear bodies, sug-
gesting a transient or indirect association (LaMorte et
al. 1998). Retinoblastoma protein (pRB), which regu-
lates cell proliferation by controlling a set of transcrip-
tion factors, has been localized to PML nuclear bodies
and forms a stable complex with PML when pRB is
hypophosphorylated (Alcalay et al. 1998). Nascent RNA
has also been localized to the interior, electron-densepart
of some PML nuclear bodies, suggesting that these struc-
tures act as a transcriptional regulator (LaMorte et al.
1998).
Dynamic Organization
Two dramatic examples of the dynamic nature of PML
bodies are the disruption of these structures in APL (fig.
2) and their enlargement in virally infected cells. The
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Figure 2 PML nuclear bodies disrupted in APL cells. PML nu-
clear bodies in non-APL leukemia blasts are shown, top, as detected
by indirect IF using a specific PML antibody. In APL-derived NB4
cells, which express PML/RARa, a microparticulate pattern of PML
staining is observed. In cells cultured with arsenic, there is a degra-
dation of the PML/RARa fusion protein, which leads to a reformation
of PML nuclear bodies and subsequent apoptosis (Zhu et al. 1997).
NB4 cells cultured in the presence of ATRA are able to differentiate.
The PML/RARa fusion protein is degraded, and this is accompanied
by reformation of PML nuclear bodies (Dyck et al. 1994; Weis et al.
1994).
PML protein occurs in similar-sized structures in both
the nucleus and the cytoplasm (Stuurman et al. 1997),
and the continual incorporation and release of PML
from nuclear bodies has led to the suggestion that PML
(and possibly other components of the PML nuclear
bodies) shuttles between nuclear and cytoplasmic struc-
tures (Stuurman et al. 1997).
The number and size of PML nuclear bodies varies
throughout the cell cycle. The smallest average number
is seen in G0, slowly increasing during progression to
G1, with the highest number observed in S phase (Terris
et al. 1995; Koken et al. 1995). A weak, nuclear-diffuse
form of PML is visible by IF at G0, intensifying as the
cell progresses to S phase (Koken et al. 1995; Terris et
al. 1995). Sp100 and PML colocalize at all stages during
the cell cycle except during mitosis, when PML forms
large aggregates at the periphery of the cell and Sp100
is distributed more diffusely (reviewed in Sternsdorf et
al. 1997). The localization of all the components
throughout the cell cycle is not known, but many of the
transitory interactions among components of PML nu-
clear bodies are likely to be sensitive to the cell cycle.
Several components, including pRB, are themselves im-
plicated in cell cycle regulation. PML, too, regulates cell
cycle progression by modulating the expression of cell
cycle regulatory proteins, including Cdk2 and cyclin E
(Mu et al. 1997). It will be interesting to determine in
more detail the role of PML nuclear bodies and their
components in cell cycle regulation.
A number of chemical reagents or alterations in cell
growth conditions can significantly affect the morphol-
ogy and number of PML nuclear bodies. Cystine-defi-
cient media, for example, cause a reversible increase in
the size of the nuclear bodies, whereas histidine- or me-
thionine-deficient media have no such effect (Kamei
1997). PML nuclear bodies are also affected by stress
factors such as heavy metals and heat shock proteins.
Heat shock changes the PML nuclear-body distribution
into a microspeckled pattern, and, as the cell recovers,
tracklike structures are observed, which finally form nor-
mal nuclear bodies (Maul et al. 1995).
Mutagenesis based on the three-dimensional structure
of the PML RING finger revealed that a number of do-
mains of PML, in particular the RBCC motif, can influ-
ence the formation of PML nuclear bodies (Borden et
al. 1995; Boddy et al. 1997). Mutations of the RING
finger cysteines result in a nuclear-diffuse but matrix-
associated PML when overexpressed, whereas specific
surface residue mutations result in abnormally large
PML nuclear bodies (Boddy et al. 1997). Other studies
have shown that the B-box and coiled-coil domains also
influence nuclear-body formation (Kastner et al. 1992;
Borden et al. 1996). PML can homo-oligomerize
through the coiled-coil domain, although this is not suf-
ficient for the formation of PML nuclear bodies in vivo
(Borden et al. 1996). Loss of PML nuclear-body for-
mation has also been linked to a loss of growth and
transformation activity of PML (Le et al. 1996), al-
though recent contradictory studies suggest that locali-
zation of PML to PML nuclear bodies is not necessary
for it to suppress cell growth (Fagioli et al. 1998).
The Effect of Interferon and Viral Infection on PML
Nuclear Bodies
Interferons are a family of secreted cytokines with an-
tiviral, antiproliferative, and immunomodulatory activ-
ities (reviewed in Darnell et al. 1994). IFN treatment
leads to an enlargement in both the size and the number
of PML nuclear bodies. The expression of PML, Sp100,
and ISG20 (reviewed in Sternsdorf et al. 1997) are all
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inducible by both type I (a/b) and type II (g) IFNs. PML
has been shown to contribute to the IFN antiviral action
(Doucas et al. 1996; Chelbi-Alix et al. 1998).
Altered localization of PML and structural changes
within PML nuclear bodies have been shown to occur
during DNA and RNA viral infections (reviewed in Dou-
cas and Evans 1996; Sternsdorf et al. 1997). Some ex-
amples are as follows: the T-cell leukemia virus type 1
(HTLV-1) tax oncoprotein, which induces the specific
redistribution of INT-6 (Desbois et al. 1996), and the
adenovirus, which targets the viral protein E4-ORF3 to
PML nuclear bodies and causes their reorganization
from spherical to fibrous structures (termed “nuclear
tracks”; reviewed in Doucas and Evans 1996). Nuclear
bodies are also reorganized after human cytomegalovi-
rus (CMV) infection (Kelly et al. 1995; Korioth et al.
1996)
The herpes simplex virus type 1 (HSV-1) immediate-
early protein Vmw110 (also called “ICP0”) transiently
colocalizes with and subsequently disrupts PML nuclear
bodies (Everett and Maul 1994). Recently, it has been
shown that Vmw110 binds specifically to HAUSP (see
above), which, at early stages of viral infection, increases
the proportion of PML nuclear bodies that contain
HAUSP (Everett et al. 1997). The cytoplasmic RNA vi-
rus lymphocytic choriomeningitis (LCMV) also affects
the distribution of PML nuclear bodies, with the Z pro-
tein of LCMV interacting with PML to form large cy-
toplasmic bodies (Borden et al. 1998). Nuclear bodies
are sites for the early stages of transcription and repli-
cation of DNA and RNA viruses and are also sites for
the subsequent cellular antiviral defense mechanisms us-
ing IFNs.
Functions of PML Nuclear Bodies
Despite the indications that the proper organization
of PML-body components is essential for normal cell
proliferation, the functions of these bodies remains elu-
sive after numerous and wide-ranging studies. Recent
results, with the ablation of PML by homologous re-
combination, show that mice are viable but more sus-
ceptible to tumorigenesis and infections (Wang et al.
1998). The phenotype of these PML/ mice supports
the role of PML as a negative growth regulator and
tumor suppressor and as a specific regulator of hema-
topoietic differentiation (Wang et al. 1998). The pres-
ence of nascent RNA and the transcriptional coactivator
CBP within the internal core of PML nuclear bodies
suggests that these structures act as transcriptional reg-
ulators (LaMorte et al. 1998), and, indeed, Alcalay et
al. (1998) have found that PML can abolish activation
of glucocorticoid receptor–regulated transcription by
pRB. PML nuclear bodies have also been observed to
be closely associated with replication domains in middle
to late S phase (Grande et al. 1996). Also, viral tran-
scripts and replication factories produced during viral
infections have been localized to areas adjacent to PML
bodies, suggesting that viral transcription requires some
PML nuclear-body components (Ishov et al. 1997).
The exact molecular mechanism by which PML and
PML nuclear bodies carry out any of these functions,
however, remains to be elucidated. One possibility is that
PML nuclear bodies act as “nuclear dumps” or storage
“PODS,” where different proteins can be deposited or
stored and subsequently distributed where necessary. An
alternative theory is that PML bodies localize PML NB
components to their functionally active site either within
the nuclear body or adjacent to it.
PML Nuclear Bodies and Human Disease
In addition to being targeted by a wide range of viral
infections, PML nuclear bodies, particularly PML, are
involved in other human disease processes. Indeed, it
was the characterization of genetic changes underlying
APL that actually led to the discovery of PML and its
localization within nuclear-body structures (reviewed in
Grimwade and Solomon 1997). APL, one of the com-
monest subtypes of acute myeloid leukemia, is charac-
terized by a block in differentiation leading to replace-
ment of the bone marrow with abnormal promyelocytes.
This differentiation block can be overcome by retinoids
such as all-trans-retinoic acid (ATRA), which induces
complete remission in the majority of patients and has
transformed clinical practice (Grimwade and Solomon
1997, and references therein). A reciprocal transloca-
tion, t(15;17) (q22;q21), which leads to a rearrangement
between genes encoding PML and RARa, is almost in-
variably found in APL tumor cells (Grimwade and Sol-
omon 1997). RARa is a member of the steroid hormone
nuclear receptor family that mediates the effect of reti-
noic acid at specific DNA response elements. When
RARa is complexed with its ligand, the corepressor com-
plex, which includes SMRT (silencing mediator of re-
tinoid and thyroid receptor) or N-CoR and histone de-
acetylase (HDAC), dissociates from the receptor, thus
allowing transcriptional activation (Chambon 1996). In
addition, retinoid responses are dependent on members
of the distinct retinoid–X-receptor family, which heter-
odimerize with RARa and mediate high-affinity binding
to specific DNA response elements. The t(15; 17) typi-
cally leads to the formation of two fusion gene products,
PML/RARa and RARa/PML. Most studies have focused
on PML/RARa, since it retains the RBCC motif of PML
as well as key functional domains of RARa (reviewed
in Grimwade and Solomon 1997). The critical role
played by PML/RARa in APL is also supported by trans-
genic mice studies (Brown et al. 1997; Grisolano et al.
1997; He et al. 1998) and by the characterization of
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APL cases in which PML/RARa is the sole fusion gene
formed (Grimwade et al. 1997).
RARa has been implicated in normal hemopoiesis
(Tsai and Collins 1993), suggesting that the PML/RARa
fusion might cause APL by inhibiting the wild-type re-
ceptor. However, recent studies have demonstrated that
expression of mutant RARa (Tsai and Collins 1993) or
overexpression of normal receptor (Onodera et al. 1995)
block myeloid differentiation but are insufficient to in-
duce APL, suggesting that the PML-derived portion of
the fusion protein is essential for leukemic transforma-
tion. It has also become apparent that expression of the
PML/RARa fusion protein disrupts PML nuclear bodies
(fig. 2; Dyck et al. 1994; Weis et al. 1994). In cells derived
from normal and neoplastic tissues or from hematolog-
ical malignancies other than APL, !30 such nuclear bod-
ies are typically observed, whereas, in APL cases with
the t(15;17) translocation, a characteristic, microspec-
kled PML nuclear-staining pattern is detected (fig. 2;
Dyck et al. 1994; Weis et al. 1994). Treatment of APL
cells with ATRA causes the fusion protein to be degraded
and restores the normal PML nuclear-staining pattern;
parallel with these events, cellular differentiation re-
sumes (fig. 2). Similarly, reversion to a wild-type pattern
of PML staining has been observed when APL blasts are
exposed to arsenic compounds (fig. 2; Zhu et al. 1997).
However, it has been noted that some cases of APL with
PML/RARa rearrangements are resistant to retinoids
and maintain a microparticulate PML nuclear-staining
pattern (Dyck et al. 1994). This suggests that disruption
of PML bodies could play a fundamental role in the
pathogenesis of APL and that reversal of this process is
essential to overcoming the block in differentiation that
characterizes APL (Dyck et al. 1994). Furthermore, PML
appears to function as a growth suppressor (Mu et al.
1994; Wang et al. 1998; Le et al. 1998), raising the
possibility that disruption of PML nuclear bodies in APL
could also be important in promoting leukemic
transformation.
Further insights into the mechanisms underlying the
differentiation block in APL have been gained by the
characterization of a series of rare cases of APL lacking
the t(15;17) translocation, in which RARa was found
to be fused to novel partner genes. These include the
Kru¨ppel-like zinc finger gene PLZF (reviewed in Pandolfi
1996), the gene encoding the nuclear mitotic apparatus
protein (NuMA; Wells et al. 1997), and the nucleo-
phosmin gene (NPM; Pandolfi 1996), whose gene prod-
uct is involved in RNA processing. These fusion proteins
form as a result of t(11;17)(q23;q21), t(11;17)(q13;q21),
and t(5;17)(q32;q21) rearrangements, respectively. Of
these rare APL-associated translocations, the best stud-
ied is the PLZF/RARa rearrangement. Although PLZF
and PML bear little structural similarity, both suppress
cell growth in a transformation assay (Pandolfi 1996),
and both are localized to discrete, possibly related nu-
clear domains. However, in contrast to t(15;17) APL
patients, those with a PLZF/RARa rearrangement do
not resume differentiation when treated with ATRA
alone. It is now clear that this reflects differential binding
of the PML/RARa and PLZF/RARa fusion proteins to
nuclear corepressors such as SMRT or N-COR (He et
al. 1997; Grignani et al. 1998; Guidez et al. 1998; Lin
et al. 1998). At physiological levels of RA, both fusion
proteins bind the corepressor complex, leading to re-
pression of retinoid response elements. In the presence
of pharmacological levels of ATRA, binding of ligand
to the fusion proteins is associated with displacement of
N-COR/SMRT and HDAC from the PML/RARa recep-
tor complex. In the case of PML/RARa, this leads to
transcriptional activation at retinoid response elements.
However, because PLZF/RARa binds the complex
through a second, ATRA-insensitive site, ATRA fails to
activate transcription in t(11;17) APL cells.
Recent studies have suggested that PLZF can interact
directly with PML in vivo (Koken et al. 1997), suggesting
that disruption of PML nuclear bodies could be a com-
mon feature in the pathogenesis of APL. However, in
APL cases associated with PLZF/RARa (Grimwade et
al. 1997), NuMA/RARa (Wells et al. 1997), and NPM/
RARa (Redner et al. 1997), a wild-type pattern of PML-
staining has been observed, suggesting that PML nuclear
bodies are intact in these cases. Therefore, disruption of
PML nuclear bodies may not be an essential component
of the differentiation block in APL. This is in agreement
with in vitro studies showing that the differentiation
block and ATRA response are independent of delocal-
ization of PML from nuclear bodies (Grignani et al.
1996).
Whether the growth-suppressor effects attributed to
PML—or, indeed, to PLZF—are mediated by the pro-
teins themselves or require other nuclear-body constit-
uents remains to be established. Disruption of PML nu-
clear bodies may act specifically in the etiology of
t(15;17)-associated APL, possibly by causing putative
growth suppressors such as PML, pRB, or PLZF to be
mislocalized. Interestingly, recent cotransfection studies
involving PML/RARa and PLZF/RARa show that both
fusion proteins colocalize to microspeckles (Koken et al.
1997), implying that some common mislocalization is
involved in all forms of APL. Further characterization
of the components of PML nuclear bodies and their in-
tranuclear dynamics in APL may provide further insights
into the process of leukemogenesis and the response to
retinoids and arsenic compounds.
APL is not the only human disease that is linked with
an alteration in the localization of PML nuclear bodies.
Disruption of these bodies is also observed in spinocer-
ebellar ataxia type I (SCA1), a neurogenerative disorder.
Normal ataxin-1 protein is associated with the nuclear
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matrix, whereas expression of a mutant ataxin-1 asso-
ciated with SCA1 causes the specific redistribution of
PML from the nuclear bodies; however, there does not
seem to be a general loss of nuclear structure integrity,
because three other nuclear components were unaffected
by the expression of mutant ataxin-1 (Skinner et al.
1997). Whether this contributes to SCA1 development
or is a result of SCA1 is not known, but it is interesting
that these bodies appear to be disrupted.
Recent progress in understanding nuclear organiza-
tion has shown it to be highly organized and dynamic.
Future studies will increase our understanding of how
the nuclear compartments are assembled in a precise
temporal and spatial manner and how disruption of this
organization contributes to human disease.
Acknowledgment
We would like to thank Estelle Duprez for help with the
figures.
References
Ahn MJ, Langenfeld J, Moasser MM, Rusch V, Dmitrovsky
E (1995) Growth suppression of transformed human bron-
chial epithelial cells by all-trans-retinoic acid occurs through
specific retinoid receptors. Oncogene 11:2357–2364
Alcalay M, Tomassoni L, Colombo E, Stoldt S, Grignani F,
Fagioli M, Szekely L, et al (1998) The promyelocytic leu-
kemia gene product (PML) forms stable complexes with the
retinoblastoma protein. Mol Cell Biol 18:1084–1093
Ascoli CA, Maul GG (1991) Identification of a novel nuclear
domain. J Cell Biol 112:785–795
Boddy MN, Duprez E, Borden KL, Freemont PS (1997) Surface
residue mutations of the PML RING finger domain alter the
formation of nuclear matrix–associated PML bodies. J Cell
Sci 110:2197–2205
Boddy MN, Howe K, Etkin LD Solomon E, Freemont PS
(1996) PIC 1, a novel ubiquitin-like protein which interacts
with the PML component of a multiprotein complex that is
disrupted in acute promyelocytic leukemia. Oncogene 13:
971–982
Borden KL, Boddy MN, Lally J, O’Reilly NJ, Martin S, Howe
K, Solomon E, et al (1995) The solution structure of the
RING finger domain from the acute promyelocytic leukemia
proto-oncoprotein PML. EMBO J 14:1532–1541
Borden KL, Campbell Dwyer EJ, Salvato MS (1998) An ar-
enavirus RING (zinc-binding) protein binds the oncoprotein
promyelocyte leukemia protein (PML) and relocates PML
nuclear bodies to the cytoplasm. J Virol 72:758–766
Borden KL, Lally JM, Martin SR, O’Reilly NJ, Solomon E,
Freemont PS (1996) In vivo and in vitro characterization of
the B1 and B2 zinc-binding domains from the acute pro-
myelocytic leukemia protooncoprotein PML. Proc Natl
Acad Sci USA 93:1601–1606
Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci
PG, Atwater S, et al (1997) A PML/RARa transgene initiates
murine acute promyelocytic leukemia. Proc Natl Acad Sci
USA 94:2551–2556
Cao T, Duprez E, Borden KL, Freemont PS, Etkin LD (1998)
Ret finger protein is a normal component of PML nuclear
bodies and interacts directly with PML. J Cell Sci 111:
1319–1329
Chambon P (1996) A decade of molecular biology of retinoic
acid receptors. FASEB J 10:940–954
Chelbi-Alix MK, Quignon F, Pelicano L, Koken MH, de The
H (1998) Resistance to virus infection conferred by the in-
terferon-induced promyelocytic leukemia protein. J Virol 72:
1043–1051
Darnell JE Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways
and transcriptional activation in response to IFNs and other
extracellular signaling proteins. Science 264:1415–1421
Desbois C, Rousset R, Bantignies F, Jalinot P (1996) Exclusion
of Int-6 from PML nuclear bodies by binding to the HTLV-
I Tax oncoprotein. Science 273:951–953
Doucas V, Evans RM (1996) The PML nuclear compartment
and cancer. Biochim Biophys Acta 1288:M25-M29
Doucas V, Ishov AM, Romo A, Juguilon H, Weitzman MD,
Evans RM, Maul GG (1996) Adenovirus replication is cou-
pled with the dynamic properties of the PML nuclear struc-
ture. Genes Dev 10:196–207
Dyck JA, Maul GG, Miller WH Jr, Chen JD, Kakizuka A,
Evans RM (1994) A novel macromolecular structure is a
target of the promyelocyte-retinoic acid receptor oncopro-
tein. Cell 76:333–343
Everett RD, Freemont P, Saitoh H, Dasso M, Orr A, Kathoria
M, Parkinson J (1998) The disruption of ND10 during her-
pes simplex virus infection correlates with the Vmw110 and
proteasome-dependent loss of several PML isoforms. J Virol
72:6581–6591
Everett RD, Maul GG (1994) HSV-1 IE protein Vmw110
causes redistribution of PML. EMBO J 13:5062–5069
Everett RD, Meredith M, Orr A, Cross A, Kathoria M, Par-
kinson J (1997) A novel ubiquitin-specific protease is dy-
namically associated with the PML nuclear domain and
binds to a herpesvirus regulatory protein. EMBO J 16:
1519–1530
Fagioli M, Alcalay M, Tomassoni L, Ferrucci PF, Mencarelli
A, Riganelli D, Grignani F, et al (1998) Cooperation between
the RING and B1-B2 and coiled coil domains of PML is
necessary for its effect on cell survival. Oncogene 16:
2905–2913
Ferreira J, Paolella G, Ramos C, Lamond AI (1997) Spatial
organization of large-scale chromatin domains in the nu-
cleus: a magnified view of single chromosome territories. J
Cell Biol 139:1597–1610
Gongora C, David G, Pintard L, Tissot C, Hua TD, Dejean
A, Mechti N (1997) Molecular cloning of a new interferon-
induced PML nuclear body-associated protein. J Biol Chem
272:19457–19463
Grande MA, van der Kraan I, van Steensel B, Schul W, de The
H, van der Voort HT, de Jong L, et al (1996) PML-con-
taining nuclear bodies: their spatial distribution in relation
to other nuclear components. J Cell Biochem 63:280–291
Grignani F, de Matteis S, Nervi C, Tomassoni L, Gelmetti V,
Cioce M, Fanelli M, et al (1998) Fusion proteins of the
Hodges et al.: Nuclear Structure ’98 303
retinoic acid receptor-a recruit histone deacetylase in pro-
myelocytic leukemia. Nature 391:815–818
Grignani F, Testa U, Rogaia D, Ferrucci PF, Samoggia P, Pinto
A, Aldinucci D, et al (1996) Effects on differentiation by the
promyelocytic leukemia PML/RARa protein depend on the
fusion of the PML protein dimerization and RARa DNA
binding domains. EMBO J 15:4949–4958
Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S,
Oliver F, Walker H, et al (1997) Characterization of cryptic
rearrangements and variant translocations in acute pro-
myelocytic leukemia. Blood 90:4876–4885
Grimwade D, Solomon E (1997) Characterisation of the PML/
RARa rearrangement associated with t(15;17) acute pro-
myelocytic leukemia. Curr Top Microbiol Immunol 220:
81–112
Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ (1997)
Altered myeloid development and acute leukemia in trans-
genic mice expressing PML/RARa under control of cathep-
sin G regulatory sequences. Blood 89:376–387
Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent
A (1998) Reduced retinoic acid-sensitivities of nuclear re-
ceptor corepressor binding to PML/ and PLZF/RARa un-
derlie molecular pathogenesis and treatment of acute pro-
myelocytic leukemia. Blood 91:2634–2642
He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent
A, Pandolfi PP (1998) Distinct interactions of PML/RARa
and PLZF/RARa with co- repressors determine differential
responses to RA in APL. Nat Genet 18:126–135
He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V,
Cattoretti G, et al (1997) Acute leukemia with promyelocytic
features in PML/RARa transgenic mice. Proc Natl Acad Sci
USA 94:5302–5307
Ishov AM, Maul GG (1996) The periphery of nuclear domain
10 (ND10) as site of DNA virus deposition. J Cell Biol 134:
815–826
Ishov AM, Sternberg RM, Maul GG (1997) Human cyto-
megalovirus immediate early interaction with host nuclear
structures: definition of an immediate transcript environ-
ment. J Cell Biol 138:5–6
Jackson DA (1995) Nuclear organization: uniting replication
foci chromatin domains and chromosome structure. Bioes-
says 17:587–591
Kamei H (1997) Cystine starvation induces reversible large-
body formation from nuclear bodies in T24 cells. Exp Cell
Res 237:207–216
Kastner P, Perez A, Lutz Y, Rochette-Egly C, Gaub MP, Durand
B, Lanotte M, et al (1992) Structure localization and tran-
scriptional properties of two classes of retinoic acid receptor
alpha fusion proteins in acute promyelocytic leukemia
(APL): structural similarities with a new family of oncopro-
teins. EMBO J 11:629–642
Kelly C, Van Driel R, Wilkinson GW (1995) Disruption of
PML-associated nuclear bodies during human cytomegalo-
virus infection. J Gen Virol 76:2887–2893
Koken MH, Linares-Cruz G, Quignon F, Viron A, Chelbi-Alix
MK, Sobczak-Thepot J, Juhlin L, et al (1995) The PML
growth-suppressor has an altered expression in human on-
cogenesis. Oncogene 10:1315–1324
Koken MH, Reid A, Quignon F, Chelbi-Alix MK, Davies JM,
Kabarowski JH, Zhu J, et al (1997) Leukemia-associated
retinoic acid receptor alpha fusion partners PML and PLZF
heterodimerize and colocalize to nuclear bodies. Proc Natl
Acad Sci USA 94:10255–10260
Korioth F, Maul GG, Plachter B, Stamminger T, Frey J (1996)
The nuclear domain 10 (ND10) is disrupted by the human
cytomegalovirus gene product IE1. Exp Cell Res 229:
155–158
Lamond AI, Earnshaw WC (1998) Structure and function in
the nucleus. Science 280:547–553
LaMorte VJ, Dyck JA, Ochs RL, Evans RM (1998) Locali-
zation of nascent RNA and CREB binding protein with the
PML-containing nuclear body. Proc Natl Acad Sci USA 95:
4991–4996
Le XF, Vallian S, Mu ZM, Hung MC, Chang KS (1998) Re-
combinant PML adenovirus suppresses growth and tumor-
igenicity of human breast cancer cells by inducing G1 cell
cycle arrest and apoptosis. Oncogene 16:1839–1849
Le XF, Yang P, Chang KS (1996) Analysis of the growth and
transformation suppressor domains of promyelocytic leu-
kemia gene PML. J Biol Chem 271:130–135
Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM
(1998) Role of the histone deacetylase complex in acute
promyelocytic leukemia. Nature 391:811–814
Matera AG, Frey MR (1998) Coiled bodies and gems: Janus
or Gemini? Am J Hum Genet 63:317–321 (in this issue)
Maul GG, Yu E, Ishov AM, Epstein AL (1995) Nuclear domain
10 (ND10) associated proteins are also present in nuclear
bodies and redistribute to hundreds of nuclear sites after
stress. J Cell Biochem 59:498–513
Mu ZM, Chin KV, Liu JH, Lozano G, Chang KS (1994) PML,
a growth suppressor disrupted in acute promyelocytic leu-
kemia. Mol Cell Biol 14:6858–67
Mu ZM, Le XF, Vallian S, Glassman AB, Chang KS (1997)
Stable overexpression of PML alters regulation of cell cycle
progression in HeLa cells. Carcinogenesis 18:2063–2069
Muller S, Matunis MJ, Dejean A (1998) Conjugation with the
ubiquitin-related modifier SUMO-1 regulates the partition-
ing of PML within the nucleus. EMBO J 17:61–70
Nickerson JA, Blencowe BJ, Penman S (1995) The architectural
organization of nuclear metabolism. Int Rev Cytol 162A:
67-123
Onodera M, Kunisada T, Nishikawa S, Sakiyama Y, Matsu-
moto S, Nishikawa S (1995) Overexpression of retinoic acid
receptor alpha suppresses myeloid cell differentiation at the
promyelocyte stage. Oncogene 11:1291–1298
Pandolfi PP (1996) PML, PLZF, and NPM genes in the mo-
lecular pathogenesis of acute promyelocytic leukemia. Hae-
matologica 81:472–482
Redner RL, Rush EA, Schesinger EW, Pollock SL, Watkins SC
(1997) The t(5-17) APL fusion protein NPM-RAR does not
alter PML localisation. Blood 90:1431
Saurin AJ, Borden KL, Boddy MN, Freemont PS (1996) Does
this have a familiar RING? Trends Biochem Sci 21:208–214
Scheer U, Weisenberger D (1994) The nucleolus. Curr Opin
Cell Biol 6:354–359
Shikama N, Lyon J, La Thangue NB (1997) The p300/CBP
family: integrating signals with transcription factors and
chromatin. Trends Cell Biol 7:230–236
304 Am. J. Hum. Genet. 63:297–304, 1998
Skinner PJ, Koshy BT, Cummings CJ, Klement IA, Helin K,
Servadio A, Zoghbi HY, et al (1997) Ataxin-1 with an ex-
panded glutamine tract alters nuclear matrix-associated
structures. Nature 389:971–974 (erratum [1998] Nature
391:307)
Sternsdorf T, Grotzinger T, Jensen K, Will H (1997) Nuclear
dots: actors on many stages. Immunobiology 198:307–331
Stuurman N, Floore A, Middelkoop E, van Driel R, de Jong
L (1997) PML shuttles between nuclear bodies and the cy-
toplasm. Cell Mol Biol Lett 2:137–150
Takahashi M, Inaguma Y, Hiai H, Hirose F (1988) Develop-
mentally regulated expression of a human “finger”–
containing gene encoded by the 5′ half of the ret transform-
ing gene. Mol Cell Biol 8:1853–1856
Terris B, Baldin V, Dubois S, Degott C, Flejou JF, Henin D,
Dejean A (1995) PML nuclear bodies are general targets for
inflammation and cell proliferation. Cancer Res 55:
1590–1597
Tsai S, Collins SJ (1993) A dominant negative retinoic acid
receptor blocks neutrophil differentiation at the promyelo-
cyte stage. Proc Natl Acad Sci USA 90:7153–7157
Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-
Cardo C, Grosveld F, et al (1998) Role of PML in cell growth
and the retinoic acid pathway. Science 279:1547–1551
Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-
Fonseca M, Lamond A, et al (1994) Retinoic acid regulates
aberrant nuclear localization of PML/RARa in acute pro-
myelocytic leukemia cells. Cell 76:345–356
Wells RA, Catzavelos C, Kamel-Reid S (1997) Fusion of re-
tinoic acid receptor alpha to NuMA the nuclear mitotic ap-
paratus protein by a variant translocation in acute promye-
locytic leukemia. Nat Genet 17:109–113
Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L,
Wang ZY, Chen Z, et al (1997) Arsenic-induced PML tar-
geting onto nuclear bodies: implications for the treatment
of acute promyelocytic leukemia. Proc Natl Acad Sci USA
94:3978–3983
